PMI Launches Unregistered Disposable E-Cigarette Brand in UK

May.29.2023
PMI Launches Unregistered Disposable E-Cigarette Brand in UK
PMI's VEEBA disposable e-cigarette brand lacks registration with UK's MHRA, in violation of regulatory requirements.

On February 28th, PMI International announced the launch of VEEBA, a disposable e-cigarette brand, in the UK. However, on May 29th, it was revealed that the brand had not been registered with the Medicines and Healthcare Products Regulatory Agency (MHRA) by PMI International, according to 2FIRSTS.


It is understood that the online data information collection period of the UK MHRA is from August 21, 2021, to May 27, 2023, and is updated daily with the latest registration information.


The image source for VEEBA on the IQOS UK online sales platform.


However, according to the regulations set by the UK regulatory authority, all electronic cigarettes and e-liquids entering the British market must be registered with MHRA before being launched. This registration can be carried out by brand owners, distributors, transporters, and other relevant parties. According to inquiries by 2FIRSTS, the international electronic cigarette brand VEEV, VEEV NOW, and VEEV ONE have been included in the registration list. It is understood that VEEV is a pod vape, VEEV NOW is a disposable e-cigarette, and VEEV ONE is a rechargeable device. However, no relevant registration information has been found for VEEBA.


Has VEEBA registered with the MHRA under the brand name VEEV NOW? While the registered brand name is VEEV NOW, the products are sold under the brand name VEEBA. Is this compliant? 2FIRSTS has reached out to PMI and the MHRA for comment on this issue, but as of publication time, no response has been received. 2FIRSTS will continue to monitor and update on this topic. Stay tuned.


VEEV is listed in the registration information of MHRA. Image source: MHRA.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Exhibition Insights | Beyond Devices: What RELX’s Multi-Format Display Suggests About Category Expansion
Exhibition Insights | Beyond Devices: What RELX’s Multi-Format Display Suggests About Category Expansion
RELX’s booth in Prague brought together vaping devices, RELX-branded e-liquids, oral nicotine products and a nasal product concept in one display. Rather than centering the booth on a single hardware line, the company presented multiple product paths side by side.
Apr.20 by 2FIRSTS.ai
    Shenzhen Tobacco Monopoly Bureau Moves to Advance E-Cigarette Regulatory System 2.0
Shenzhen Tobacco Monopoly Bureau Moves to Advance E-Cigarette Regulatory System 2.0
The Shenzhen Tobacco Monopoly Bureau recently held the city’s 2026 e-cigarette regulation work conference to implement higher-level meeting requirements, review the city’s e-cigarette regulatory work in 2025 and during the 14th Five-Year Plan period, assess the current situation, and deploy the rollout of E-cigarette Regulatory System 2.0 across Shenzhen’s tobacco commercial system.
Apr.28 by 2FIRSTS.ai
Product|PMI Expands High-Strength Nicotine Pouch Portfolio With Zyn 16.5mg
Product|PMI Expands High-Strength Nicotine Pouch Portfolio With Zyn 16.5mg
According to Better Retailing, Philip Morris International (PMI) has launched Zyn Menthol Ice 16.5mg in the UK, marking the highest-strength nicotine pouch in the Zyn range to date. The eucalyptus- and menthol-flavored product is now available through PMI Open and will begin rolling out to wholesale channels from the end of May.
PMI
May.28
Acting CTP Director Says FDA Cut Premarket Tobacco Application Backlog by About 70% Over the Past Year
Acting CTP Director Says FDA Cut Premarket Tobacco Application Backlog by About 70% Over the Past Year
FDA Center for Tobacco Products Acting Director Bret Koplow said at the American Tobacco and Nicotine Forum that the agency has reduced its premarket tobacco application backlog by about 70% over the past year and eliminated the acceptance queue. He said FDA has reviewed about 27 million applications, but only a small number have been authorized, mainly because most submissions lacked the scientific data needed to demonstrate public health benefits.
Apr.23 by 2FIRSTS.ai
Philip Morris International Says Part of Owensboro ZYN Output Is Exceeding Market Demand
Philip Morris International Says Part of Owensboro ZYN Output Is Exceeding Market Demand
Philip Morris International said its Swedish Match facility in Owensboro will adjust part of its production schedule this summer in response to changing market conditions. According to a notice the company gave union leadership and employees on April 22, parts of ZYN production will shift from a 24/7 schedule back to a 24/5 schedule. The ZYN Flagship department will return to a five-day, three-shift operation.
Apr.23 by 2FIRSTS.ai
 Bangladesh Approves Amended Tobacco Control Law Expanding Ad Bans and Smoke-Free Areas
Bangladesh Approves Amended Tobacco Control Law Expanding Ad Bans and Smoke-Free Areas
Bangladesh’s new government has approved a broad tobacco control amendment that bans tobacco advertising, promotion and display across print, electronic, digital and social media, entertainment platforms and points of sale. The law does not cover newer products such as vapes, heated tobacco products, electronic nicotine delivery systems or nicotine pouches.
Apr.22 by 2FIRSTS.ai